Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors.

Autor: Matsuoka, Hideo, Yano, K., Katsuta, Yasaburo, Morita, Masaru, Kounoe, Syunji, Seo, Yousuke, Saito, Takao, Tomoda, Hirotsugu
Zdroj: Cancer Chemotherapy & Pharmacology; Sep1996, Vol. 38 Issue 6, p508-512, 5p
Abstrakt: To target the treatment of small points of cancer, Beriplast P, already used clinically as a physiological tissue adherent drug carrier, was mixed with the anticancer drug, mitomycin C (MMC). In this in vitro study, MMC did not release quickly from the clot of MMC/Beriplast P. The antitumor effect of this mixture was examined for its effect on cancer growth. In one series of experiments, tumor tissues were inoculated with MMC/100 μl Beriplast P and in another series, MMC/100 μl Beriplast P was injected into tumors at a weight of 300 mg. In the first series of experiments, tumor tissue treated with 0.3 mg MMC/100 μl Beriplast P was replaced with plasma cells and lymphocytes, and no viable cancer cells could be found. In the second series, MMC/100 μl Beriplast P delayed tumor growth, and the survival of Balb/c mice injected with 0.08 mg MMC/100 μl Beriplast P was significantly longer than that of mice injected with 0.08 mg MMC/100 μl saline solution ( P=0.026). In addition, the abdominal aorta, vena cava, and intestine around the area of treatment with 1.6 mg MMC/100 μl Beriplast P were not damaged. These results indicate that the mixture of Beriplast P and MMC is more effective than MMC solution alone in the local treatment of residual cancer. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index